Today, the CEO of Harvard Bioscience (NASDAQ: HBIO), Jeffrey Duchemin, bought shares of HBIO for $646.5K.
Following this transaction Jeffrey Duchemin’s holding in the company was increased by 20.25% to a total of $4.94 million. In addition to Jeffrey Duchemin, 4 other HBIO executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Harvard Bioscience’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $31.52 million and GAAP net loss of $1.49 million. In comparison, last year the company earned revenue of $25.21 million and had a GAAP net loss of $381K. Currently, Harvard Bioscience has an average volume of 549.2K.
Starting in November 2016, HBIO received 4 Buy ratings in a row.
The insider sentiment on Harvard Bioscience has been positive according to 48 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harvard Bioscience, Inc. develops, manufactures, and markets broad range of specialized products, primarily apparatus and scientific instruments. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force.
